We hope today is manageable and productive. Best of luck, and keep in touch. … GSK plans to depart the biotechnology industry ...
GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac heartburn remedy causes cancer. The British drugmaker’s settlement ...
Haleon was spun off from GSK amid investor pressure, showing steady growth but facing debt concerns. See more about HLN stock ...
This writer thinks GSK shares appear very cheap after the Q3 results, making him wonder if now's the time for him to invest ...
Analysis of the full trial data, including the key secondary endpoint of overall survival (OS), is ongoing, but at the moment that data is “immature”, said GSK. In October, GSK reported new ...
Coolers full of vaccine strapped to their motorbikes ... mostly, as she is unable to form words. Her mother, Nazma, had been outside with the baby when we arrived; in these rooms nine families ...
GSK was able to avert industrial action at some of its UK facilities last year after agreeing a pay deal – but with the cost-of-living crisis still in full swing ... and other form of borrowing.
ViiV Healthcare Announces Data Demonstrating Dovato (DTG/3TC) Is Highly Effective in Treatment-Naïve People With Advanced HIV ...
KellyFact checked by Vikki VelasquezAmerican taxpayers complain about a wide range of tax features but studies by the Pew Research Center consistently reveal that a majority express concern that some ...
In a dramatic turn of events that makes for some great storytelling, Cidara's novel drug-Fc conjugate, once locked up in a ...
Please consult the full Summary of Product Characteristics ... those described under Item 3.D “Risk factors” in GSK’s Annual Report on Form 20-F for 2023, and GSK’s Q2 Results for 2024.